Latest filingSep 01, 2026Most recent Form 4
XERS
Xeris Biopharma Holdings, Inc.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 08/03 to 09/03. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$31.1M3 sells
Net open-market-$31.1M3 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period3transactions
- S · Open-market sells · dominant3 · 100%
Activity by reported role
A joint filing can contribute to multiple roles3transactions
- SR · dominant3 · 100%
Distinct insiders active
Reporting-owner CIKs by month · peak Sep 2026 (3)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typePieper StevenCommon Stock · Direct
1,356,053Sep 01, 2026
Hecht BethCommon Stock · Direct
1,127,796Sep 01, 2026
McCulloch KevinCommon Stock · Direct
1,639,208Sep 01, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 03 → Sep 03
LessMore
Top insiders
By absolute net value across the selected period- HB-$141.4k
- MK-$127.3k
- PS-$42.5k
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
XERS transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| XERS | McCulloch Kevin | SR | sale10b5-1 | 15.0k | -$12.7M | S | 0.0% | 09/01 | 09/01 | |
| XERS | Hecht Beth | SR | sale10b5-1 | 16.6k | -$14.1M | S | 0.0% | 09/01 | 09/01 | |
| XERS | Pieper Steven | SR | sale10b5-1 | 5.00k | -$4.25M | S | 0.0% | 09/01 | 09/01 |
Xeris Biopharma Holdings, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Xeris Biopharma Holdings, Inc.?
McCulloch Kevin, Hecht Beth, Pieper Steven.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
McCulloch Kevin reported a sale on Sep 01, 2026 valued at $12.7M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $311,242.34. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.